Adlai Nortye Group (ANL) vs Alto Neuroscience (ANRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Alto Neuroscience (ANRO) over the past year, gaining 712.1% versus a gain of 296.0%. Adlai Nortye Group is the larger company by market cap ($998.8 million vs $943.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | ANRO |
|---|---|---|
| Share price | $15.51 | $24.03 |
| Market cap | $998.81M | $942.99M |
| 1-day change | +10.39% | +2.17% |
| YTD return | +889.44% | +32.13% |
| 1-year return | +712.14% | +295.96% |
| EPS (TTM) | $-0.66 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $37.48 |
| 52-week low | $0.879 | $5.23 |
| Distance from 52-week high | -10.09% | -35.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +90.20% | +59.72% |
| Average volume | 175.26K | 540.09K |
| Shares outstanding | 58.73M | 39.24M |
| Employees | 109 | 68 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed ANRO by 416.2 percentage points over the past year.
- The two companies sit in different sectors: Adlai Nortye Group in Healthcare and Alto Neuroscience in Health Care.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Healthcare · Biotechnology · 109 employees
About Alto Neuroscience
ANRO stock →Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees
ANL vs ANRO FAQ
Which is bigger, Adlai Nortye Group or Alto Neuroscience?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $998.81M compared with $942.99M for Alto Neuroscience (ANRO).
Which stock has performed better over the past year, ANL or ANRO?
ANL returned +712.14% over the past 12 months, compared with +295.96% for ANRO (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Alto Neuroscience in the same industry?
No. Adlai Nortye Group is in the Healthcare sector, while Alto Neuroscience is in Health Care.